4.5 Review

Mechanisms, biomarkers and targets for adult-onset Still's disease

期刊

NATURE REVIEWS RHEUMATOLOGY
卷 14, 期 10, 页码 603-618

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41584-018-0081-x

关键词

-

资金

  1. AbbVie
  2. Biogen
  3. BMS
  4. Celgene
  5. Janssen
  6. Lilly
  7. Medac
  8. MSD
  9. Nordic Pharma
  10. Novartis
  11. Pfizer
  12. Roche
  13. Sanofi-Aventis
  14. Swedish Orphan Biovitrum
  15. UCB

向作者/读者索取更多资源

Adult-onset Still's disease (AoSD) is a rare but clinically well-known, polygenic, systemic autoinflammatory disease. Owing to its sporadic appearance in all adult age groups with potentially severe inflammatory onset accompanied by a broad spectrum of disease manifestation and complications, AoSD is an unsolved challenge for clinicians with limited therapeutic options. This Review provides a comprehensive insight into the complex and heterogeneous nature of AoSD, describing biomarkers of the disease and its progression and the cytokine signalling pathways that contribute to disease. The efficacy and safety of biologic therapeutic options are also discussed, and guidance for treatment decisions is provided. Improving the approach to AoSD in the future will require much closer cooperation between paediatric and adult rheumatologists to establish common diagnostic strategies, treatment targets and goals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据